AU2003227257A1 - Medicine for prevention and/or therapy of cardiomyopathy - Google Patents

Medicine for prevention and/or therapy of cardiomyopathy

Info

Publication number
AU2003227257A1
AU2003227257A1 AU2003227257A AU2003227257A AU2003227257A1 AU 2003227257 A1 AU2003227257 A1 AU 2003227257A1 AU 2003227257 A AU2003227257 A AU 2003227257A AU 2003227257 A AU2003227257 A AU 2003227257A AU 2003227257 A1 AU2003227257 A1 AU 2003227257A1
Authority
AU
Australia
Prior art keywords
cardiomyopathy
therapy
medicine
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003227257A
Inventor
Tetsuya Hayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Pharma Corp
Original Assignee
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Pharma Corp filed Critical Mitsubishi Pharma Corp
Publication of AU2003227257A1 publication Critical patent/AU2003227257A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003227257A 2002-03-27 2003-03-27 Medicine for prevention and/or therapy of cardiomyopathy Abandoned AU2003227257A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002-087499 2002-03-27
JP2002087499 2002-03-27
PCT/JP2003/003813 WO2003080583A1 (en) 2002-03-27 2003-03-27 Medicine for prevention and/or therapy of cardiomyopathy

Publications (1)

Publication Number Publication Date
AU2003227257A1 true AU2003227257A1 (en) 2003-10-08

Family

ID=28449389

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003227257A Abandoned AU2003227257A1 (en) 2002-03-27 2003-03-27 Medicine for prevention and/or therapy of cardiomyopathy

Country Status (3)

Country Link
JP (1) JPWO2003080583A1 (en)
AU (1) AU2003227257A1 (en)
WO (1) WO2003080583A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005120031A (en) * 2003-10-17 2005-05-12 Pola Chem Ind Inc Orally administrable composition for diabetic complication
JP6013197B2 (en) * 2011-02-16 2016-10-25 株式会社セルシード Labeling agent for post-translational modification analysis of serine and threonine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2342251A1 (en) * 1998-08-28 2000-03-09 Scios Inc. Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase
CO5271699A1 (en) * 2000-01-24 2003-04-30 Pfizer Prod Inc PROCEDURE FOR THE TREATMENT OF CARDIOMIOPATIA USING INHIBITORS OF THE GLUCOGENO FOSFORILASA
JPWO2003024446A1 (en) * 2001-09-11 2004-12-24 三菱ウェルファーマ株式会社 Oxidative stress inhibitor and method for measuring oxidative stress

Also Published As

Publication number Publication date
WO2003080583A1 (en) 2003-10-02
JPWO2003080583A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2003219934A1 (en) Method of treatment or prevention of obesity
AU2003256253A1 (en) Aerosol for medical treatment and methods
AU2003298043A1 (en) Surface treatment of medical device
AU2004208615B2 (en) Medicine for prevention of and treatment for arteriosclerosis and hypertension
AU2002952811A0 (en) Hyperbaric therapy capsule
AU2003300791A1 (en) Combination therapy for the treatment of pain
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU2003279442A1 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
AU2002323823A1 (en) Medicament for prevention and treatment of fracture and osteoporosis
AU2003263760A1 (en) Methods for the treatment or prevention of obesity
AU2002364171A1 (en) Materials and methods for the treatment or prevention of obesity
AU2003262230A1 (en) Preventive and/or therapeutic drugs for itch
AU2003262229A1 (en) Preventive and/or therapeutic drugs for asthma
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
AU2003231279A1 (en) Prevention and treatment of type 2 diabetes
AU2003227257A1 (en) Medicine for prevention and/or therapy of cardiomyopathy
AU2003268939A1 (en) Bisphosphonates for the treatment of antheroscleorosis and devices comprising them
AU2003216810A1 (en) Combination ofa cdk inhibitor and 5-fu for the treatment of cancer
AU2003300772A1 (en) Preventive and therapeutic aids vaccines
AU2003264954A1 (en) Pharmaceutical composition for prevention and treatment of kidney diseases
AU2003280688A1 (en) Combination therapy of peptide vaccination and estramustine treatment
AU2003223216A1 (en) Artelinic acid-l-lysine salt for treatment of severe and complicated malaria
AU2003235665A1 (en) Diagnostic and therapeutic uses of topors

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase